Skip to main content
. Author manuscript; available in PMC: 2015 Sep 11.
Published in final edited form as: Clin Cancer Res. 2015 Feb 27;21(11):2471–2479. doi: 10.1158/1078-0432.CCR-14-2332

Figure 3.

Figure 3

Cell viability assays of various anti-hypertensive agents with or without sunitinib at differing concentrations on A-498 (A) and 769-P (B) RCC cells and various anti-hypertensive agents with or without temsirolimus at differing concentrations on A-498 (C) and 769-P (D) RCC cells. The combination of sunitinib with captopril or lisinopril at 10 μM and above concentrations significantly decreased A-498 and 769-P RCC cell viability when compared to DMSO.